Erin Grannan, PharmD, BCOP, on Treating Early-Stage Triple-Negative Breast Cancer With Pembrolizumab and Chemotherapy

Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the KEYNOTE-522 trial and new phase III findings of interest to advanced practitioners. In the study, researchers found a generally consistent event-free survival benefit among patients with early-stage high-risk triple-negative breast cancer who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab (Abstract GS1-01).